Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- Prognostic biomarkers of distant metastasis following curative-intent resection of early-stage rectal cancer.Clinical proteomics · 2026Article
- CD8Cancer science · 2026Article
- Profiling the tumor immunological status in Japanese solid cancers using the tumor immune status scoring algorithm.Scientific reports · 2026Article
- Integration of radiomics, deep learning, transcriptomics, and metabolomics reveals prognostic risk stratification and underlying biological mechanisms in colorectal cancer.NPJ precision oncology · 2026Article
- Traditional Chinese medicine remodels the immune microenvironment of colorectal cancer: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- Immunoscore based on CD3American journal of cancer research · 2026Article
- The immune microenvironment of colorectal cancer.Nature reviews. Cancer · 2025Review
- Oral microbiota-responsive ZIF nanoplatform via double-layer glycans modified combined with PD-1 inhibitor for treatment of microsatellite-stable colorectal cancer.Materials today. Bio · 2025Article
- A Paired Flow Cytometry-Pathology Assessment for Immune Cell Detection in Intestinal Biopsies: Proof of Principle.Methods and protocols · 2025Article
- CD103Clinical and translational medicine · 2025Article
- Multimodal tumor microenvironment signature of colorectal cancer for prediction prognosis and chemotherapy benefit.NPJ precision oncology · 2025Article
- Research progress on mechanisms of tumor immune microenvironment and gastrointestinal resistance to immunotherapy: mini review.Frontiers in immunology · 2025Review
- Research progress on immunotherapy combined with neoadjuvant concurrent chemoradiotherapy in pMMR/MSS locally advanced rectal cancer.Frontiers in immunology · 2025Review
- Intratumoural CD8Cancer immunology, immunotherapy : CII · 2024Article
- Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More.South Asian journal of cancer · 2024Review
- A novel semi-quantitative scoring method for CD8+ tumor-infiltrating lymphocytes based on infiltration sites in gastric cancer.American journal of cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHigh densities of tumor infiltrating CD3 and CD8 T-cells are associated with superior prognosis in colorectal cancer (CRC). Their value as predictors of benefit from adjuvant chemotherapy is uncertain. PATIENTS AND
methodsTumor tissue from 868 patients in the QUASAR trial (adjuvant fluorouracil/folinic acid
resultsIn the training set, the recurrence rate in the high-risk group was twice that in the low-risk group for all measures (CD3-CT: rate ratio [RR], 2.00,
conclusionRecurrence rates in the high-risk CD3/CD8 groups are twice those in the low-risk groups. Proportional reductions with chemotherapy are similar, allowing NNTs derived in QUASAR to be updated using contemporary, nonrandomized data sets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.